

**CIN: L40100TN1992PLC129301**

05-08-2021

**To,**

Dept. of Corporate Services  
Bombay Stock Exchange Limited  
Floor 25, P J Tower, Dalal Street,  
Mumbai 400001

**(Scrip code: 526445)**

Dear Sir/Madam

**Sub: Merged financial results pursuant to the Hon'ble NCLT order dated 05-08-2020**

With respect to the e-mail received from BSE for attaching the statement of assets and liabilities in the merged financial results of previous years submitted by us, we are herewith attaching the statement of assets and liabilities for the half year ended September 2018 & 2019 and for the year ended 31<sup>st</sup> March 2019.

The entire financial result for the aforementioned periods has also been attached for reference.

Kindly take the same on your record.

Thanking you

Yours Sincerely,



**ROOPA RAVIKUMAR**

**Company Secretary & Compliance Officer**

**Indrayani Biotech Limited**



**INDRAYANI BIOTECH LIMITED**

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy  
Chennai Tamil Nadu 600032.

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2018**
**Rs. In Lakhs**

	PARTICULARS				
Sr No	PARTICULARS	3 months ended 30-09-2018	3 months ended 30-09-2017	Year to date figures for current period ended 30-09-2018	Previous Year ended 31-03-2017
A	Date of start of reporting period	01-07-2018	01-07-2017	01-04-2018	01-04-2016
B	Date of end of reporting period	30-09-2018	30-09-2017	30-09-2018	31-03-2017
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	<b>Income from Operations</b>				
	(a) Net Sales/Revenue from Operations	1,113.62		1,922.49	
	(b) Other Income	8.17		17.48	
	<b>Total Income from Operations</b>	1,121.79		1,939.97	
2	<b>Expenses</b>				
	(a) Cost of Materials consumed	776.88		1,319.13	
	(b) Purchase of stock-in-trade				
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade				
	(d) Employee benefits expenses	315.90	0.90	551.44	2.70
	(e) Finance Costs	26.25	0.02	55.97	0.03
	(f) Depreciation and amortisation expense	22.81		43.45	
	Total Other expenses	90.52	1.31	155.19	7.66
	<b>Total Expenses</b>	1,232.36	2.23	2,125.16	10.39
3	<b>Total profit / (Loss) before exceptional items and tax</b>	(110.57)	(2.23)	(185.20)	(10.39)
4	Exceptional Items				
5	<b>Total profit / (Loss) before tax</b>	(110.57)	(2.23)	(185.20)	(10.39)
7	<b>Tax Expenses</b>				
8	Current Tax				
9	Deferred Tax				
10	<b>Total Tax Expenses</b>				
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
12	<b>Net Profit Loss for the period from continuing operations</b>	(110.57)	(2.23)	(185.20)	(10.39)
13	<b>Profit (loss) from discontinued operations before tax</b>				
14	<b>Tax expense of discontinued operations</b>				
15	<b>Net profit (loss) from discontinued operation after tax</b>				
16	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>				
17	<b>Total profit (loss) for period</b>	(110.57)	(2.23)	(185.20)	(10.39)
18	<b>Other comprehensive income net of taxes</b>				
19	<b>Total Comprehensive Income for the period</b>				
20	<b>Total profit or loss, attributable to</b>				
	Profit or loss, attributable to owners of parent	(110.57)	(2.23)	(185.20)	(10.39)
	Total profit or loss, attributable to non-controlling interests				
21	<b>Total Comprehensive income for the period attributable to</b>				

	Comprehensive income for the period attributable to owners of parent				
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests				
<b>22</b>	<b>Details of equity share capital</b>				
	Paid-up equity share capital				
	Face value of equity share capital				
<b>23</b>	<b>Details of debt securities</b>				
	Paid-up debt capital	3,422.72	364.39	3,422.72	364.39
	Face value of debt securities	10.00	10.00	10.00	10.00
<b>24</b>	<b>Reserves excluding revaluation reserve</b>				
<b>25</b>	<b>Debenture redemption reserve</b>				
<b>26</b>	<b>Earnings per share</b>				
<b>i</b>	<b>Earnings per equity share for continuing operations</b>	(0.32)	(0.06)	(0.54)	(0.29)
	Basic earnings (loss) per share from continuing operations	(0.32)	(0.06)	(0.54)	(0.29)
	Diluted earnings (loss) per share from continuing operations				
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
<b>iii</b>	<b>Earnings per equity share</b>				
	Basic earnings (loss) per share from continuing and discontinued operations	(0.32)	(0.06)	(0.54)	(0.29)
	Diluted earnings (loss) per share from continuing and discontinued operations	(0.32)	(0.06)	(0.54)	(0.29)
<b>27</b>	<b>Debt equity ratio</b>				
<b>28</b>	<b>Debt service coverage ratio</b>				
<b>29</b>	<b>Interest service coverage ratio</b>				
<b>30</b>	<b>Disclosure of notes on financial results</b>				

Notes:

1. The unaudited merged financial results for the Quarter ended 30-09-2018 being forwarded to the Bombay stock exchange and is also available in the website of the Company ([www.indrayani.com](http://www.indrayani.com) )
2. The above financial results have been pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05-08-2020.
3. The Company operates in single business segment. Hence no segment wise reporting figures are published.
4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter.
5. Previous period figures have been regrouped wherever necessary.



Place: Chennai  
Date: 22-06-2021

A handwritten signature in blue ink, appearing to read "K. Sayee Sundar".

K SAYEE SUNDAR  
MANAGING DIRECTOR  
DIN: 01295584



M/s. INDRAYANI BIOTECH LIMITED		
Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.		
Balance sheet as at 30th September 2018		
	Rs. In Lakhs	
Particulars	30-09-2018	31-03-2018
<b>ASSETS</b>		
<b>A) Non - Current Assets</b>		
a) Property Plant and Equipment	1,337.19	
b) Capital Work in Progress	1,065.41	
c) Goodwill	383.53	
d) Other Intangible assets		
e) Financial Assets		
--- (i) Investments	0.44	
--- (ii) Other Financial Assets		
f) Other Non Current assets	82.96	
<b>B) Current Assets</b>		
a) Inventories	950.26	
b) Financial Assets		
--- (i) Investments		
--- (ii) Trade Receivables	744.71	
--- (iii) Cash and cash Equivalents	47.38	1.05
--- (iii) Other Financial Assets	5.06	
c) Other Current assets	167.45	
<b>Total Assets</b>	<b>4,784.39</b>	<b>1.05</b>
<b>EQUITY &amp; LIABILITIES</b>		
<b>A) Equity</b>		
a) Equity Share Capital	3,422.72	364.39
b) Other Equity	-609.71	-424.52
<b>B) LIABILITIES</b>		
<b>Non - Current Liabilities</b>		
a) Financial Liabilities		
--- (i) Borrowings	639.57	60.00
--- (ii) Other financial Liabilities		
b) Deferred Tax Liabilities	1.38	
c) Other Non Current Liabilities		
<b>Current Liabilities</b>		
a) Financial Liabilities		
--- (i) Short Term Borrowings	592.21	
--- (ii) Trade Payables		
----- (A) total outstanding dues of micro enterprises and small enterprises;		
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	615.06	0.44
--- (iii) Other financial Liabilities		
b) Other Current Liabilities	25.79	0.09
c) Provisions	97.37	0.65
<b>Total Equity &amp; Liabilities</b>	<b>4,784.39</b>	<b>1.05</b>

K. durgu Indu



**INDRAYANI BIOTECH LIMITED**

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy  
Chennai Tamil Nadu 600032.

**AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March 2019**
**Rs. In Lakhs**

	PARTICULARS				
Sr No	PARTICULARS	3 months ended 31-03-2019	3 months ended 31-03-2018	Year ended 31-03-2019	Previous Year ended 31-03-2018
A	Date of start of reporting period	01-01-2019	01-01-2018	01-04-2018	01-04-2017
B	Date of end of reporting period	31-03-2019	31-03-2018	31-03-2019	31-03-2018
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	<b>Income from Operations</b>				
	(a) Net Sales/Revenue from Operations	1,455.29		4,697.81	
	(b) Other Income	21.24		45.04	
	<b>Total Income from Operations</b>	<b>1,476.53</b>		<b>4,742.85</b>	
2	<b>Expenses</b>				
	(a) Cost of Materials consumed	951.24		2,995.94	
	(b) Purchase of stock-in-trade				
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade				
	(d) Employee benefits expenses	320.32	1.20	1,172.93	2.70
	(e) Finance Costs	28.95	0.03	111.57	0.03
	(f) Depreciation and amortisation expense	33.67		108.62	
	(g) Other expenses	70.93	3.04	317.44	7.66
	<b>Total Expenses</b>	<b>1,405.11</b>	<b>4.27</b>	<b>4,706.51</b>	<b>10.39</b>
3	<b>Total profit / (Loss) before exceptional items and tax</b>	<b>71.42</b>	<b>(4.27)</b>	<b>36.34</b>	<b>(10.39)</b>
4	Exceptional Items				
5	<b>Total profit / (Loss) before tax</b>	<b>71.42</b>	<b>(4.27)</b>	<b>36.34</b>	<b>(10.39)</b>
7	<b>Tax Expenses</b>				
8	Current Tax	6.53		20.34	
9	Deferred Tax	3.61		11.24	
10	<b>Total Tax Expenses</b>	<b>10.14</b>		<b>31.58</b>	
	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
	<b>Net Profit Loss for the period from continuing operations</b>				
12		61.28	(4.27)	4.76	(10.39)
13	<b>Profit (loss) from discontinued operations before tax</b>				
14	<b>Tax expense of discontinued operations</b>				
	<b>Net profit (loss) from discontinued operation after tax</b>				
15					
	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>				
16					
17	<b>Total profit (loss) for period</b>	<b>61.28</b>	<b>(4.27)</b>	<b>4.76</b>	<b>(10.39)</b>
18	<b>Other comprehensive income net of taxes</b>				
19	<b>Total Comprehensive Income for the period</b>				
20	<b>Total profit or loss, attributable to</b>				
	Profit or loss, attributable to owners of parent	61.28	(4.27)	4.76	(10.39)
	Total profit or loss, attributable to non-controlling interests				
	<b>Total Comprehensive income for the period attributable to</b>				
21					

	Comprehensive income for the period attributable to owners of parent				
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests				
<b>22</b>	<b>Details of equity share capital</b>				
	Paid-up equity share capital	3,422.72	364.39	3,422.72	364.39
	Face value of equity share capital	10.00	10.00	10.00	10.00
<b>23</b>	<b>Details of debt securities</b>				
	Paid-up debt capital				
	Face value of debt securities				
<b>24</b>	<b>Reserves excluding revaluation reserve</b>				
<b>25</b>	<b>Debenture redemption reserve</b>				
<b>26</b>	<b>Earnings per share</b>				
<b>i</b>	<b>Earnings per equity share for continuing operations</b>	0.18	(0.12)	0.01	(0.29)
	Basic earnings (loss) per share from continuing operations	0.18	(0.12)	0.01	(0.29)
	Diluted earnings (loss) per share from continuing operations				
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
<b>iii</b>	<b>Earnings per equity share</b>				
	Basic earnings (loss) per share from continuing and discontinued operations	0.18	(0.12)	0.01	(0.29)
	Diluted earnings (loss) per share from continuing and discontinued operations	0.18	(0.12)	0.01	(0.29)
<b>27</b>	<b>Debt equity ratio</b>				
<b>28</b>	<b>Debt service coverage ratio</b>				
<b>29</b>	<b>Interest service coverage ratio</b>				
<b>30</b>	<b>Disclosure of notes on financial results</b>				

Notes:

1. The audited merged financial results for the Quarter ended 31-03-2019 being forwarded to the Bombay stock exchange and is also available in the website of the Company ([www.indrayani.com](http://www.indrayani.com))
2. The above financial results have been pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05-08-2020.
3. The Company operates in single business segment. Hence no segment wise reporting figures are published.
4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter.
5. Previous period figures have been regrouped wherever necessary.



Place: Chennai  
Date: 22-06-2021

A handwritten signature in blue ink, appearing to read "K. Sayee Sundar".

K SAYEE SUNDAR  
MANAGING DIRECTOR  
DIN: 01295584

M/s. INDRAYANI BIOTECH LIMITED		
Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.		
Balance sheet as at 31st March 2019		
	Rs. In Lakhs	
Particulars	31-03-2019	31-03-2018
<b>ASSETS</b>		
<b>A) Non - Current Assets</b>		
a) Property Plant and Equipment	1,402.37	
b) Capital Work in Progress	1,065.41	
c) Goodwill	383.53	
d) Other Intangible assets		
e) Financial Assets		
--- (i) Investments	0.44	
--- (ii) Other Financial Assets		
f) Other Non Current assets	106.24	
<b>B) Current Assets</b>		
a) Inventories	852.20	
b) Financial Assets		
--- (i) Investments		
--- (ii) Trade Receivables	793.38	
--- (iii) Cash and cash Equivalents	39.11	1.05
--- (iii) Other Financial Assets	50.23	
c) Other Current assets	323.19	
<b>Total Assets</b>	<b>5,016.09</b>	<b>1.05</b>
<b>EQUITY &amp; LIABILITIES</b>		
<b>A) Equity</b>		
a) Equity Share Capital	3,422.72	364.39
b) Other Equity	-419.76	-424.52
<b>B) LIABILITIES</b>		
<b>Non - Current Liabilities</b>		
a) Financial Liabilities		
--- (i) Borrowings	709.63	60.00
--- (ii) Other financial Liabilities		
b) Deferred Tax Liabilities	1.38	
c) Other Non Current Liabilities		
<b>Current Liabilities</b>		
a) Financial Liabilities		
--- (i) Short Term Borrowings	675.50	
--- (ii) Trade Payables		
----- (A) total outstanding dues of micro enterprises and small enterprises:		
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	486.63	0.44
--- (iii) Other financial Liabilities		
b) Other Current Liabilities	45.03	0.09
c) Provisions	94.97	0.65
<b>Total Equity &amp; Liabilities</b>	<b>5,016.09</b>	<b>1.05</b>

K. durgadevi



**INDRAYANI BIOTECH LIMITED**

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy  
Chennai Tamil Nadu 600032.

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2019**
**Rs. In Lakhs**

	PARTICULARS				
Sr No	PARTICULARS	3 months ended 30-06-2019	3 months ended 31-03-2019	3 months ended 30-06-2018	Previous Year ended 31-03-2019
A	Date of start of reporting period	01-04-2019	01-01-2019	01-04-2018	01-04-2018
B	Date of end of reporting period	30-06-2019	30-03-2019	30-06-2018	31-03-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	<b>Income from Operations</b>				
	(a) Net Sales/Revenue from Operations	1,013.55	1,455.29	808.87	<b>4,697.81</b>
	(b) Other Income	2.98	21.24	9.31	45.04
	<b>Total Income from Operations</b>	<b>1,016.53</b>	<b>1,476.53</b>	<b>818.18</b>	<b>4,742.85</b>
2	<b>Expenses</b>				
	(a) Cost of Materials consumed	712.63	951.24	542.25	2,995.94
	(b) Purchase of stock-in-trade				
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade				
	(d) Employee benefits expenses	307.94	320.32	235.53	1,172.93
	(e) Finance Costs	27.82	28.95	29.72	111.57
	(f) Depreciation and amortisation expense	19.27	33.67	20.64	108.62
	(g) Other expenses	79.70	70.93	64.67	317.44
	<b>Total Expenses</b>	<b>1,147.37</b>	<b>1,405.11</b>	<b>892.81</b>	<b>4,706.51</b>
3	<b>Total profit / (Loss) before exceptional items and tax</b>	<b>(130.84)</b>	<b>71.42</b>	<b>(74.63)</b>	<b>36.34</b>
4	Exceptional Items				
5	<b>Total profit / (Loss) before tax</b>	<b>(130.84)</b>	<b>71.42</b>	<b>(74.63)</b>	<b>36.34</b>
7	<b>Tax Expenses</b>				
8	Current Tax		6.54		20.34
9	Deferred Tax		3.61		11.24
10	<b>Total Tax Expenses</b>		<b>10.15</b>		<b>31.58</b>
	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
11	<b>Net Profit Loss for the period from continuing operations</b>	<b>(130.84)</b>	<b>61.27</b>	<b>(74.63)</b>	<b>4.76</b>
13	<b>Profit (loss) from discontinued operations before tax</b>				
14	<b>Tax expense of discontinued operations</b>				
15	<b>Net profit (loss) from discontinued operation after tax</b>				
16	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>				
17	<b>Total profit (loss) for period</b>	<b>(130.84)</b>	<b>61.27</b>	<b>(74.63)</b>	<b>4.76</b>
18	<b>Other comprehensive income net of taxes</b>				
19	<b>Total Comprehensive Income for the period</b>				
20	<b>Total profit or loss, attributable to</b>				
	Profit or loss, attributable to owners of parent	(130.84)	61.27	(74.63)	4.76
	Total profit or loss, attributable to non-controlling interests				
21	<b>Total Comprehensive income for the period attributable to</b>				
	Comprehensive income for the period attributable to owners of parent				

	Total comprehensive income for the period attributable to owners of parent noncontrolling interests				
<b>22</b>	<b>Details of equity share capital</b>				
	Paid-up equity share capital	3,422.72	364.39	3,422.72	364.39
	Face value of equity share capital	10.00	10.00	<b>10.00</b>	10.00
<b>23</b>	<b>Details of debt securities</b>				
	Paid-up debt capital				
	Face value of debt securities				
<b>24</b>	<b>Reserves excluding revaluation reserve</b>				
<b>25</b>	<b>Debenture redemption reserve</b>				
<b>26</b>	<b>Earnings per share</b>				
<b>i</b>	<b>Earnings per equity share for continuing operations</b>	(0.38)	<b>0.18</b>	<b>(0.22)</b>	<b>0.01</b>
	Basic earnings (loss) per share from continuing operations	(0.38)	<b>0.18</b>	<b>(0.22)</b>	<b>0.01</b>
	Diluted earnings (loss) per share from continuing operations				
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
<b>iii</b>	<b>Earnings per equity share</b>				
	Basic earnings (loss) per share from continuing and discontinued operations	(0.38)	0.18	(0.22)	0.01
	Diluted earnings (loss) per share from continuing and discontinued operations	(0.38)	0.18	(0.22)	0.01
<b>27</b>	<b>Debt equity ratio</b>				
<b>28</b>	<b>Debt service coverage ratio</b>				
<b>29</b>	<b>Interest service coverage ratio</b>				
<b>30</b>	<b>Disclosure of notes on financial results</b>				

Notes:

1. The unaudited merged financial results for the Quarter ended 30-06-2019 being forwarded to the Bombay stock exchange and is also available in the website of the Company ([www.indrayani.com](http://www.indrayani.com) )
2. The above financial results have been pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05-08-2020.
3. The Company operates in single business segment. Hence no segment wise reporting figures are published.
4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter.
5. Previous period figures have been regrouped wherever necessary.



Place: Chennai  
Date: 22-06-2021

A handwritten signature in blue ink, appearing to read 'K. Sayee Sundar'.

K SAYEE SUNDAR  
MANAGING DIRECTOR  
DIN: 01295584



	INDRAYANI BIOTECH LIMITED				
	Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.				
	UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2019				
	Rs. In Lakhs				
	PARTICULARS				
Sr No	PARTICULARS	3 months ended 30-09-2019	3 months ended 30-09-2018	Year to date figures for current period ended 30-09-2019	Previous Year ended 31-03-2018
A	Date of start of reporting period	01-07-2019	01-07-2018	01-04-2019	01-04-2017
B	Date of end of reporting period	30-09-2019	30-09-2018	30-09-2019	31-03-2018
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	<b>Income from Operations</b>				
	(a) Net Sales/Revenue from Operations	1,201.33	1,113.62	2,214.88	4,697.81
	(b) Other Income	6.04	8.17	9.02	45.04
	<b>Total Income from Operations</b>	1,207.38	1,121.79	2,223.90	4,742.85
2	<b>Expenses</b>				
	(a) Cost of Materials consumed	726.83	776.88	1,439.47	2,995.94
	(b) Purchase of stock-in-trade				
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade				
	(d) Employee benefits expenses	276.49	315.90	584.43	1,172.93
	(e) Finance Costs	27.63	26.25	55.45	111.57
	(f) Depreciation and amortisation expense	21.30	22.81	40.58	108.62
	(g) Other expenses	69.28	90.52	148.98	317.44
	<b>Total Expenses</b>	1,121.53	1,232.36	2,268.90	4,706.51
	<b>Total profit / (Loss) before exceptional items</b>				
3	<b>and tax</b>	85.84	(110.57)	(45.00)	36.34
4	Exceptional Items				
5	<b>Total profit / (Loss) before tax</b>	85.84	(110.57)	(45.00)	36.34
7	<b>Tax Expenses</b>				
8	Current Tax				20.34
9	Deferred Tax				11.24
10	<b>Total Tax Expenses</b>				31.58
	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
11					
12	<b>Net Profit Loss for the period from continuing operations</b>	85.84	(110.57)	(45.00)	4.76
13	<b>Profit (loss) from discontinued operations before tax</b>				
14	<b>Tax expense of discontinued operations</b>				
15	<b>Net profit (loss) from discontinued operation after tax</b>				
16	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>				
17	<b>Total profit (loss) for period</b>	85.84	(110.57)	(45.00)	4.76
18	<b>Other comprehensive income net of taxes</b>				
19	<b>Total Comprehensive Income for the period</b>				
20	<b>Total profit or loss, attributable to</b>				

	Profit or loss, attributable to owners of parent	85.84	(110.57)	(45.00)	4.76
	Total profit or loss, attributable to non-controlling interests				
21	<b>Total Comprehensive income for the period attributable to</b>				
	Comprehensive income for the period attributable to owners of parent				
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests				
22	<b>Details of equity share capital</b>				
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital	10.00	10.00	10.00	10.00
23	<b>Details of debt securities</b>				
	Paid-up debt capital				
	Face value of debt securities				
24	<b>Reserves excluding revaluation reserve</b>				
25	<b>Debenture redemption reserve</b>				
26	<b>Earnings per share</b>				
i	<b>Earnings per equity share for continuing operations</b>	0.25	(0.32)	(0.13)	0.01
	Basic earnings (loss) per share from continuing operations	0.25	(0.32)	(0.13)	0.01
	Diluted earnings (loss) per share from continuing operations				
ii	<b>Earnings per equity share for discontinued operations</b>				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	<b>Earnings per equity share</b>				
	Basic earnings (loss) per share from continuing and discontinued operations	0.25	(0.32)	(0.13)	0.01
	Diluted earnings (loss) per share from continuing and discontinued operations	0.25	(0.32)	(0.13)	0.01
27	<b>Debt equity ratio</b>				
28	<b>Debt service coverage ratio</b>				
29	<b>Interest service coverage ratio</b>				
30	<b>Disclosure of notes on financial results</b>				

Notes:

1. The unaudited merged financial results for the Quarter ended 30-09-2019 being forwarded to the Bombay stock exchange and is also available in the website of the Company ([www.indrayani.com](http://www.indrayani.com) )
2. The above financial results have been pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05-08-2020.
3. The Company operates in single business segment. Hence no segment wise reporting figures are published.
4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter.
5. Previous period figures have been regrouped wherever necessary.



A handwritten signature in blue ink, appearing to read "K. Sayee Sundar".

Place: Chennai  
Date: 22-06-2021

K SAYEE SUNDAR  
MANAGING DIRECTOR  
DIN: 01295584

M/s. INDRAYANI BIOTECH LIMITED		
Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.		
Balance sheet as at 30th September 2019		
	Rs. In Lakhs	
Particulars	30-09-2019	31-03-2019
<b>ASSETS</b>		
<b>A) Non - Current Assets</b>		
a) Property Plant and Equipment	1,361.79	1,402.37
b) Capital Work in Progress	1,065.41	1,065.41
c) Goodwill	383.53	383.53
d) Other Intangible assets		
e) Financial Assets		
--- (i) Investments	0.44	0.44
--- (ii) Other Financial Assets		
f) Other Non Current assets	115.47	106.24
<b>B) Current Assets</b>		
a) Inventories	852.20	852.20
b) Financial Assets		
--- (i) Investments		
--- (ii) Trade Receivables	710.89	793.38
--- (iii) Cash and cash Equivalents	32.72	39.11
--- (iii) Other Financial Assets	63.20	50.23
c) Other Current assets	270.92	323.19
<b>Total Assets</b>	<b>4,856.56</b>	<b>5,016.09</b>
<b>EQUITY &amp; LIABILITIES</b>		
<b>A) Equity</b>		
a) Equity Share Capital	3,422.72	3,422.72
b) Other Equity	-464.76	-419.76
<b>B) LIABILITIES</b>		
<b>Non - Current Liabilities</b>		
a) Financial Liabilities		
--- (i) Borrowings	613.28	709.63
--- (ii) Other financial Liabilities		
b) Deferred Tax Liabilities	1.38	1.38
c) Other Non Current Liabilities		
<b>Current Liabilities</b>		
a) Financial Liabilities		
--- (i) Short Term Borrowings	620.91	675.50
--- (ii) Trade Payables		
----- (A) total outstanding dues of micro enterprises and small enterprises;		
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	519.46	486.63
--- (iii) Other financial Liabilities		
b) Other Current Liabilities	48.55	45.03
c) Provisions	95.01	94.97
<b>Total Equity &amp; Liabilities</b>	<b>4,856.56</b>	<b>5,016.09</b>

K. dhanu

